Group 1 - The company Yongxin Co., Ltd. (SZ 002014) held a temporary board meeting on December 9, 2025, to discuss the election of non-independent directors for the ninth board [1] - For the first half of 2025, Yongxin's revenue composition was as follows: 92.98% from other plastic manufacturing, 4.24% from coatings, inks, and similar products, and 2.79% from other businesses [1] - As of the report date, Yongxin's market capitalization was 7.2 billion yuan [1] Group 2 - The news highlights a significant issue in the pharmaceutical industry regarding the abuse of pregabalin, marking the first reported case of addiction in China [1] - The report indicates vulnerabilities in online platforms that allow the purchase of medications without medical records, raising concerns about regulatory oversight [1] - The classification of pregabalin and the need for scientific evaluation regarding its regulation are emphasized [1]

Group 1 - The core point of the article is that Yongxin Co., Ltd. plans to establish a wholly-owned subsidiary in Shanghai with an investment of 5 million RMB to support its international development strategy and enhance its market share and competitiveness [1] - The decision to set up the subsidiary was approved by the company's board during its 19th meeting of the 8th session [1] - The revenue composition for Yongxin Co., Ltd. in 2024 is projected to be 92.46% from other plastic manufacturing, 4.4% from coatings, inks, and similar products, and 3.14% from other businesses [1] Group 2 - As of the report, Yongxin Co., Ltd. has a market capitalization of 7.1 billion RMB [2]